Three new clinical trials aim to assess the safety and efficacy of a new cancer immunotherapy treatment, KTE-C19, in patients with three types of treatment-resistant blood cancers — refractory aggressive non-Hodgkin lymphoma (NHL), relapsed/refractory mantle cell lymphoma and relapsed/refractory B-precursor acute lymphoblastic leukemia.
Learn more about these new clinical trials here: http://bit.ly/1QH9kWH
